Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abuse Potential of Cebranopadol in Recreational Opioid Users
NCT05256108Phase 1Completed
- Sponsor
- Tris Pharma
- Start
- Mar 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cebranopadol in pain, sponsored by Tris Pharma. Primary endpoint: Drug Liking Visual Analog Scale Emax. Started Mar 2022; status: completed.
02
Drugs
cebranopadol
03
Conditions
pain
Beyond the preview
Go deeper on NCT05256108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05256108.